SCPH SCPharmaceuticals Inc

scPharmaceuticals Inc. to Present at Upcoming Investor Conferences

scPharmaceuticals Inc. to Present at Upcoming Investor Conferences

BURLINGTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, chief executive officer, will present at the following investor conferences in June:

Jefferies 2019 Global Healthcare Conference

Presentation: Friday, June 7, 2019 at 8:30 AM EDT

Location: Grand Hyatt, New York, NY

BMO’s 2019 Prescriptions for Success Healthcare Conference

Presentation: Tuesday, June 25, 2019 at 3:20 PM EDT

Location: Mandarin Oriental, New York, NY

About scPharmaceuticals

scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, products for the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit scPharmaceuticals.com.

Contacts:

Katherine Taudvin, scPharmaceuticals Inc.

781-301-6706

Christopher F. Brinzey, Westwicke an ICR Company

339-970-2843

EN
30/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Reve...

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch